X4 Pharmaceuticals, Inc

X4 Pharmaceuticals is a biopharmaceutical company focused on developing therapeutics for rare immune system disorders. The company's primary marketed product is XOLREMDI, an oral CXCR4 antagonist approved for treatment of warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company is also advancing mavorixafor, a CXCR4 antagonist in Phase 3 development for cyclic neutropenia and severe congenital neutropenia, with a Phase 3 trial (4WARD) evaluating efficacy and safety in patients experiencing recurrent or serious infections.

X4 Pharmaceuticals has established partnerships to expand its pipeline across additional indications. The company holds a license agreement with Abbisko Therapeutics to develop and commercialize mavorixafor in combination with checkpoint inhibitors and other agents for oncology applications. A separate agreement with Norgine covers development and commercialization of mavorixafor in Europe, Australia, and New Zealand. These partnerships represent potential revenue streams beyond the company's direct commercialization efforts.

The company operates with approximately 143 full-time employees and is headquartered in Boston, Massachusetts. X4 Pharmaceuticals is incorporated in Delaware and listed on the Nasdaq exchange.